Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed ...

Analysts estimate that CureVac will report an earnings per share (EPS) of $-0.09. Investors in CureVac are eagerly awaiting ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...